Navigation Links
Amarillo Biosciences Issues Corporate Update
Date:10/14/2011

lo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza and hepatitis C. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2010. Investor Relations: Philippe Niemetz

PAN Consultants, Ltd.

e-mail:p.niemetz@panconsultants.com

Tel: 800-477-7570; 212-344-6464

Fax: 212-618-1276Investor Inquiries: Josh Tyrell

Interactive Business Alliance, LLC

e-mail: jtyrell@ibaconsultingllc.com

Tel: 866-525-4714
'/>"/>

SOURCE Amarillo Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
10. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has commenced an underwritten public offering ... grant the underwriters a 30-day option to purchase up ... common stock offered in the public offering. The offering ... no assurance as to whether or when the offering ...
(Date:4/30/2015)... , April 30, 2015 The following is ... of Directors of China Cord Blood Corp (NYSE: CO ... special committee of the independent directors of China Cord Blood ... privatization offer of $6.40 per share from Golden Meditech Holdings ... $6.40 per share would greatly benefit Golden Med and Mr. ...
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. ... in the development of biosimilar therapeutics including high ... the closing of its previously announced underwritten public ... at a public offering price of $15.50 per ... the underwriters of their option to purchase up ...
(Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... provider, today announced that its board of directors has ... 2015, from a consortium (the "Consortium") led by Dr. ... chief executive officer of the Company, and Ally Bridge ... "Transaction") involving the acquisition of all outstanding shares of ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... Genetics, the parent company of Myeloma Health, a privately ... announced the formation of their Scientific Advisory Board. They ... Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer ... Medical School Dr. Anderson of Dana-Farber Cancer ...
... AutoGenomics, a leader in providing automated, molecular testing solutions ... the U.S. Food and Drug Administration to market its ... *2, *3, *17, of the CYP450 2C19 gene and ... testing platform, the INFINITI® Analyzer.   "We ...
... ("China-Biotics", the "Company") (Nasdaq: CHBT ), the ... China, today announced it will host a conference call ... Beijing Time on Tuesday, November 9, 2010, to discuss ... financial results for the period ended September 30, 2010. ...
Cached Biology Technology:Signal Genetics Announces Establishment of Scientific Advisory Board 2Signal Genetics Announces Establishment of Scientific Advisory Board 3AutoGenomics Receives FDA Clearance for its INFINITIĀ® CYP2C19 Assay 2China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9 2
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... Science Research Conference on focuses on recent advances in ... transcriptional regulators, currently numbering 17, and will also include ... Held twice previously, this FASEB Conference is the ... The major themes of the conference will be the ...
... medicine? The media are invited to register now for ... Clinical Genetics Meeting, March 25-29, 2014 at the Nashville ... Sequencing to Cancer Genetics, the focus of the ACMG ... genomics in healthcare, showcasing the latest breakthroughs in genetics ...
... European consortium of epilepsy researchers has reported the discovery ... Using a novel combination of technologies, including trio exome ... tiny larvae of zebrafish, the EuroEPINOMICS RES consortium found ... a subset of epilepsy patients with symptoms similar to ...
Cached Biology News:Complimentary press registration now open for ACMG 2014 Annual Clinical Genetics Meeting 2European epilepsy consortium identifies new gene for severe childhood epilepsy 2European epilepsy consortium identifies new gene for severe childhood epilepsy 3European epilepsy consortium identifies new gene for severe childhood epilepsy 4
Polyclonal Antibody to PRG3...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
Polyclonal Antibody to SHPRH...
Biology Products: